TB-500 vs GHK-Cu
Thymosin Beta-4 Fragment · Copper Peptide
Here is how these two compounds compare, based on published research, not marketing claims.
TB-500
Sequesters actin to enable cell migration toward damaged tissue; the synthetic fragment of thymosin beta-4.
GHK-Cu
Delivers copper to tissue cells and modulates over 4,000 genes including collagen synthesis; available in cosmetic formulations.
TB-500
1050 studies
13 human trials
Not FDA-Approved
GHK-Cu
186 studies
4 human trials
Not FDA-Approved
What it does
TB-500
Typically a synthetic 4-amino-acid fragment of thymosin beta-4's active region (Ac-SDKP, the first four residues of the 43-amino-acid parent molecule), though commercial products labeled TB-500 vary in actual composition. Marketed as if interchangeable with full-length Tβ4, but the published human research is on the parent peptide, not the fragment. The mechanism described in animal studies (mobilization of repair cells through actin sequestration) is shared, but the evidence base for TB-500 specifically is a fraction of what exists for thymosin beta-4.
GHK-Cu
Delivers copper to skin and tissue cells, where it switches on the genes that build collagen and switches off the ones that drive aging. Naturally produced by the body; levels decline about 60 percent between the 20s and 60s.
How it works
TB-500
A copy of a fragment of a natural protein called Thymosin Beta-4. It works on actin, the scaffolding cells use to crawl through tissue. By turning up that scaffolding-rebuild process, the body's repair cells can migrate to where they're needed, and inflammatory signals get dialed down along the way.
GHK-Cu
GHK-Cu binds copper(II) and delivers it to tissue sites where copper-dependent enzymes drive repair: lysyl oxidase for collagen cross-linking, superoxide dismutase for antioxidant defense, cytochrome c oxidase for cellular energy. It also directly modulates gene expression, upregulating collagen production and stem cell recruitment while downregulating the matrix-degrading enzymes that drive aging. The breadth of gene regulation (over 4,000 genes in transcriptomic studies) is unmatched among peptides, but gene expression changes in laboratory studies are not the same as clinical outcomes in humans.
How often
TB-500
In studies, given as a twice-weekly shot under the skin. The compound stays active in the body longer than BPC-157, which is why dosing is less frequent in protocols.
GHK-Cu
Topical application in cosmetic skincare formulations with decades of commercial use history. Injectable form expected to return to legal pharmacy preparation status following the February 2026 HHS announcement. Published human research is topical; no consensus injectable dosing protocol exists in peer-reviewed literature.
How strong
TB-500
Body-wide. Unlike BPC-157's local action, TB-500's signal works wherever cells are migrating, which is anywhere repair is happening.
GHK-Cu
The widest gap between mechanistic promise and clinical validation of any compound in PSI's library. Over 4,000 genes modulated in transcriptomic analysis (Pickart and Margolina 2018). Topical cosmetic studies show measurable skin improvements. Zero controlled human trials for injectable systemic use. The mechanism is real; the human systemic evidence is not yet there.
Main tradeoff
TB-500
Bigger total research base than BPC-157, including more human studies. The catch: most of that broader work is on the parent protein, Thymosin Beta-4, not the TB-500 fragment specifically. The two don't always behave the same way.
GHK-Cu
Topical GHK-Cu shows measurable improvements in skin thickness, elasticity, and fine lines in cosmetic studies. The copper-binding mechanism and gene expression profile are well-characterized across multiple independent research groups. Whether injectable GHK-Cu produces systemic anti-aging effects in humans is not established. Long-term safety of regular injectable administration is not characterized. As a naturally occurring peptide that declines approximately 60% between the 20s and 60s, the theoretical safety profile is favorable, but theoretical safety is not established safety.
Best for
TB-500
- Research on systemic recovery across multiple sites
- Research into a body-wide repair signal rather than a localized one
- Research using twice-weekly dosing
GHK-Cu
- Research interest in copper-peptide mechanisms and broad gene modulation
- Research comparing topical versus systemic delivery of naturally occurring repair peptides
- Research contexts where the gap between transcriptomic promise and clinical validation is the central question
How to choose
A good fit for TB-500
- Research on actin-sequestering mechanisms in cell migration and tissue repair
- Research on cardiac and musculoskeletal injury repair models
- Research comparing fragment peptides (TB-500) versus full-length parent molecules (thymosin beta-4)
A good fit for GHK-Cu
- Research on broad gene modulation through copper delivery to tissue
- Research on collagen synthesis and skin repair across topical and systemic routes
- Research contexts where human cosmetic efficacy data is relevant alongside mechanistic profiling
Consider both across time
TB-500 and GHK-Cu address different bottlenecks in tissue repair. TB-500 enables the physical movement of cells toward injury sites by reorganizing the actin cytoskeleton. GHK-Cu modulates gene expression broadly, including genes that produce collagen and extracellular matrix components. The two mechanisms are complementary rather than redundant. Neither is FDA-approved. For the three-way comparison including BPC-157, see BPC-157 vs TB-500 vs GHK-Cu.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Tissue Repair
- Tissue Repair connects to Actin Regulation
- Actin Regulation promotes Cell Migration
- Cell Migration connects to Cytokine Reduction
- Cytokine Reduction connects to Cell Arrival at Injury
- Copper(II) Delivery
- Copper(II) Delivery modulates TGF-beta Signaling
- Copper(II) Delivery activates Lysyl Oxidase Activation
- TGF-beta Signaling connects to Collagen Synthesis; Lysyl Oxidase Activation connects to Collagen Synthesis
- Copper(II) Delivery connects to MMP Suppression
- Collagen Synthesis connects to Tissue Remodeling; MMP Suppression connects to Tissue Remodeling
- Copper(II) Delivery connects to Broad Gene Modulation (4,000+)
TB-500 regulates actin, the structural protein cells use to reorganize and migrate toward damaged tissue.
GHK-Cu binds copper(II) and delivers it to tissue sites, where it modulates over 4,000 genes including those that build collagen.
Research Evidence
TB-500 has primarily animal model evidence across cardiac injury, dermal wound healing, and musculoskeletal repair. The parent molecule thymosin beta-4 has more extensive published data including human ophthalmic studies (RGN-259). GHK-Cu has extensive mechanistic profiling and published human cosmetic efficacy data for topical skin applications. Injectable systemic use data is more limited for both compounds. Neither has completed Phase III trials.
- 1.
For deep tissue or cardiac healing research, TB-500 has more relevant preclinical data.
- 2.
For skin aging, collagen, or topical applications. GHK-Cu is more directly studied.
- 3.
For systemic wound healing, TB-500's actin regulation mechanism has broader tissue relevance.
- 4.
For practical, available applications today. GHK-Cu's topical formulations have more real-world use.
Key Limitations
- •No head-to-head comparison exists.
- •Both are Animal Studies with limited human clinical data.
- •TB-500 research often uses the full thymosin beta-4 protein, not the TB-500 fragment specifically.
- •GHK-Cu research spans many formulations, complicating cross-study comparison.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
TB-500
"TB-500 is the best peptide for systemic recovery after surgery"
Plausible but unproven
"Stacking TB-500 with BPC-157 covers both local and systemic healing"
Plausible but unproven
"It healed my torn rotator cuff without surgery"
Anecdotal only
GHK-Cu
"GHK-Cu is the best anti-aging peptide for skin"
Plausible but unproven
"It regrew my hair"
Anecdotal only
"Topical is just as effective as injections"
Anecdotal only
Safety Comparison
Both compounds have favorable preclinical safety profiles. TB-500 is a synthetic fragment of the endogenous protein thymosin beta-4, which is found naturally at high concentrations throughout the body. GHK-Cu is an endogenous peptide present in human plasma. Topical GHK-Cu has an established cosmetic safety record. Neither compound has long-term controlled human safety data for systemic injectable use.
TB-500
Limited human safety data. Animal studies show no serious toxicity. Not FDA-approved.
GHK-Cu
Well-tolerated topically. Endogenous, your body already makes it. Limited injectable safety data.
What the Research Suggests
Different biological targets, different practical applications. TB-500 for deep systemic tissue repair. GHK-Cu for skin and surface-level regeneration. Both are Animal Studies with room for more clinical validation.